WTO IP rights: The future of products combating COVID-19

The Biden Administration recently announced that it would support the request for a World Trade Organization (WTO) waiver of intellectual property (IP) rights under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The Indian and South African waiver request covers a broad range of intellectual property (patents, trade secrets, copyrights, and industrial designs) and medical technologies (vaccines, medical devices, therapeutics, diagnostics/tests, PPE, ventilators, materials and components, etc.) related to research, development, manufacturing, and supply of medical products for combating COVID-19.

Please join us on Tuesday, June 15 at 10:00 a.m. EDT / 4:00 p.m. CET for a discussion on the WTO waiver of IP rights with members from our Life Sciences and Health Care team, including International Trade, Intellectual Property, and Pharmaceutical and Biotechnology Regulatory practices. You will hear about what this could mean for companies with innovative products and what actions can be taken. We'll be discussing:

  • What is the WTO’s process for negotiating the terms of a TRIPS waiver?
  • What is the scope of the waiver request and what countries are impacted?
  • What are the implications for innovators of COVID-19-related technologies?
  • What does the future global access to COVID-19 vaccines look like?
  • What is next and what actions should companies be taking moving forward?

We will also be responding to questions from the audience during the discussion. If you'd like to submit a question in advance, please email Candice Ho or include the question in your registration form.

Register here


Back To Listing
Loading data